SELLAS Life Sciences Group, Inc. SLS
- galinpepimut-S — Acute Myeloid Leukemia Phase 3
- galinpepimut-S — Malignant Pleural Mesothelioma
- galinpepimut-S — Multiple Myeloma
- galinpepimut-S — Ovarian Cancer
- galinpepimut-S Preclinical
WT1 (3 companies · 10 programs)
Companies with an active program directed at WT1.
Marker Therapeutics, Inc. MRKR
- MT-601 — Non-Hodgkin Lymphoma Phase 1
- MT-601 — Pancreatic Cancer Phase 1
- MT-401-OTS — Acute Myeloid Leukemia Phase 1
- MT-401-OTS — Myelodysplastic Syndrome Phase 1
Cue Biopharma, Inc. CUE
- CUE-102